TY  - JOUR
AV  - none
KW  - CAR-T hujayra terapiyasi; timus giperplaziyasi; thymic rebound; o?tkir limfoblastik leykemiya; timus morfologiyasi
UR  - https://mjstjournal.com/index.php/mjst/article/view/5814
Y1  - 2025/11/24/
ID  - arxiv63803
A1  - Ruzieva, Maftuna
A1  - Allaberganov, Dilshod
PB  - Center for Tech and Media Research
N2  - Ushbu keng qamrovli sistematik tahlil va meta-tahlil o?tkir limfoblastik leykemiya (O?LL) bilan kasallangan bolalar va yosh kattalarda (2?26 yosh) CD19-, CD22-, dual va allogeneic CAR-T hujayra terapiyasidan keyin timusning morfologik va morfometrik o?zgarishlarini baholaydi. PRISMA 2020 yo?riqnomasiga to?liq rioya qilingan holda, 2025 yil 15 noyabrga qadar chop etilgan 23 tadqiqot (jami 1 846 bemor, shundan 1 423 nafari tisagenlecleucel olgan) kiritildi [1,7,9,18]. Random-effects model bo?yicha thymic rebound/hyperplasia chastotasi 76,8% (95% CI: 71,4?81,6%; IČ=93%), yoshroq bemorlarda (<16 yosh, 1 289 bemor) 88,7% (95% CI: 84,2?92,1%) ga yetdi. Timus hajmining standartlashtirilgan o?rtacha farqi (SMD) +5,1 baravar (95% CI: 4,6?5,7; IČ=91%, p<0,001; 19 tadqiqot, 1 623 bemor). Gistologik subguruh (12 tadqiqot): Ki-67 indeksi o?rtacha 52% (95% CI: 47?57%), Hassall tanachalari soni 3,2 baravar (95% CI: 2,8?3,6). Rebound+ guruhda 3 yillik EFS HR=0,28 (95% CI: 0,21?0,37; IČ=82%), RFS HR=0,31 (95% CI: 0,23?0,42); og?ir infektsiya RR=0,32 (95% CI: 0,25?0,41). Subguruh tahlili yosh, B-ALL fenotipi, og?ir limfodepletsiya va CAR-T persistentsiyasi bilan reboundning kuchli bog?liqligini tasdiqladi. Thymic rebound immun rekonstitutsiyaning eng ishonchli biomarkeridir va klinik monitoringda majburiy qo?llanilishi kerak.
TI  - CAR-T HUJAYRA TERAPIYASINING BOLALAR VA YOSH KATTALARDAGI O?TKIR LIMFOBLASTIK LEYKEMIYADA TIMUSNING MORFOLOGIK VA MORFOMETRIK XUSUSIYATLARIGA TA?SIRI: SISTEMATIK TAHLIL VA META-TAHLIL
N1  - Imported from MJST Journal (OAI id oai:ojs.pkp.sfu.ca:article/5814)
JF  - Multidisciplinary Journal of Science and Technology
ER  -